These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 12497762)

  • 21. The cost-effectiveness of routine office-based identification and subsequent medical treatment of primary open-angle glaucoma in the United States.
    Rein DB; Wittenborn JS; Lee PP; Wirth KE; Sorensen SW; Hoerger TJ; Saaddine JB
    Ophthalmology; 2009 May; 116(5):823-32. PubMed ID: 19285730
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Health care politicians are not concerned about maximum health gain per crown].
    Nord E
    Tidsskr Nor Laegeforen; 1993 Apr; 113(11):1371-3. PubMed ID: 8337630
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Costs and quality of life for patients with multiple sclerosis in Belgium.
    Kobelt G
    Eur J Health Econ; 2006 Sep; 7 Suppl 2():S24-33. PubMed ID: 17318662
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Priority setting and the 'neglected' tropical diseases.
    Canning D
    Trans R Soc Trop Med Hyg; 2006 Jun; 100(6):499-504. PubMed ID: 16540135
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An inquiry into the principles of needs-based allocation of health care.
    Hope T; Osterdal LP; Hasman A
    Bioethics; 2010 Nov; 24(9):470-80. PubMed ID: 19508305
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Costs and quality of life of multiple sclerosis in Germany.
    Kobelt G; Berg J; Lindgren P; Elias WG; Flachenecker P; Freidel M; König N; Limmroth V; Straube E
    Eur J Health Econ; 2006 Sep; 7 Suppl 2():S34-44. PubMed ID: 17310337
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Threshold values for cost-effectiveness ratio and public funding of medical technologies].
    Rabinovich M; Greenberg D; Shemer J
    Harefuah; 2007 Jun; 146(6):453-8, 500. PubMed ID: 17760400
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Costs and quality of life of multiple sclerosis in Spain.
    Kobelt G; Berg J; Lindgren P; Izquierdo G; Sánchez-Soliño O; Pérez-Miranda J; Casado MA;
    Eur J Health Econ; 2006 Sep; 7 Suppl 2():S65-74. PubMed ID: 17310340
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost-effectiveness of tacrolimus ointment vs. standard treatment in patients with moderate and severe atopic dermatitis: a health-economic model simulation based on a patient survey and clinical trial data.
    Hjelmgren J; Svensson A; Jörgensen ET; Lindemalm-Lundstam B; Ragnarson Tennvall G
    Br J Dermatol; 2007 May; 156(5):913-21. PubMed ID: 17263826
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost effectiveness of community-based physical activity interventions.
    Roux L; Pratt M; Tengs TO; Yore MM; Yanagawa TL; Van Den Bos J; Rutt C; Brownson RC; Powell KE; Heath G; Kohl HW; Teutsch S; Cawley J; Lee IM; West L; Buchner DM
    Am J Prev Med; 2008 Dec; 35(6):578-88. PubMed ID: 19000846
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost-effectiveness analysis of screening for lung cancer with low dose spiral CT (computed tomography) in the Australian setting.
    Manser R; Dalton A; Carter R; Byrnes G; Elwood M; Campbell DA
    Lung Cancer; 2005 May; 48(2):171-85. PubMed ID: 15829317
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical redesign using all patient refined diagnosis related groups.
    Sedman AB; Bahl V; Bunting E; Bandy K; Jones S; Nasr SZ; Schulz K; Campbell DA
    Pediatrics; 2004 Oct; 114(4):965-9. PubMed ID: 15466092
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [How much does the society want to pay?].
    Norheim OF
    Tidsskr Nor Laegeforen; 2003 Feb; 123(3):303. PubMed ID: 12640893
    [No Abstract]   [Full Text] [Related]  

  • 34. Can the "quality of life" be used as a criterion in health care services?
    Aksoy S
    Bull Med Ethics; 2000 Oct; (162):19-22. PubMed ID: 11764808
    [TBL] [Abstract][Full Text] [Related]  

  • 35. It's time to set national health care priorities.
    Kern WH
    Hosp Med Staff; 1979 Dec; 8(12):2-5. PubMed ID: 10309228
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of biotechnology-based healthcare products for prioritization in Indian context.
    Visalakshi S; Mohan S
    Int J Technol Assess Health Care; 2002; 18(3):718-27. PubMed ID: 12391962
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The evaluation of lifestyle interventions in the Netherlands.
    Rappange DR; Brouwer WB
    Health Econ Policy Law; 2012 Apr; 7(2):243-61. PubMed ID: 22380875
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cost per quality-adjusted life year and disability-adjusted life years: the need for a new paradigm.
    Bevan G; Hollinghurst S
    Expert Rev Pharmacoecon Outcomes Res; 2003 Aug; 3(4):469-77. PubMed ID: 19807457
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cost-effectiveness analysis and health policy.
    Torgerson DJ
    Nestle Nutr Workshop Ser Clin Perform Programme; 2009; 12():95-104. PubMed ID: 19858689
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Severity of illness versus expected benefit in societal evaluation of healthcare interventions.
    Nord E
    Expert Rev Pharmacoecon Outcomes Res; 2001 Oct; 1(1):85-92. PubMed ID: 19807511
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.